Beijing Science Sun Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Beijing Science Sun Pharmaceutical şirketinin toplam hissedar öz sermayesi CN¥3.4B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥3.5B ve CN¥163.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥1.53b
Eşitlik	CN¥3.35b
Toplam yükümlülükler	CN¥163.36m
Toplam varlıklar	CN¥3.52b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Investor Optimism Abounds Beijing Science Sun Pharmaceutical Co., Ltd. (SZSE:300485) But Growth Is Lacking

Oct 03

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Apr 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300485 'nin kısa vadeli varlıkları ( CN¥1.7B ) kısa vadeli yükümlülüklerini ( CN¥83.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 300485 şirketinin kısa vadeli varlıkları ( CN¥1.7B ) uzun vadeli yükümlülüklerini ( CN¥80.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300485 borçsuzdur.

Borcun Azaltılması: 300485 son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: 300485 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 300485 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Beijing Science Sun Pharmaceutical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.12 loss in 3Q 2023)

Investor Optimism Abounds Beijing Science Sun Pharmaceutical Co., Ltd. (SZSE:300485) But Growth Is Lacking

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.52 in 2Q 2023)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Dividend reduced to CN¥0.022

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

First quarter 2024 earnings released: CN¥0.40 loss per share (vs CN¥0.002 profit in 1Q 2023)

Beijing Science Sun Pharmaceutical's (SZSE:300485) Problems Go Beyond Weak Profit

Investor sentiment deteriorates as stock falls 17%

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.43 in FY 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 10, 2024

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.037 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.52 (vs CN¥0.27 in 2Q 2022)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023

First quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.22 in 1Q 2022)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.11 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.09 in 2Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Cash Dividend for the Fiscal Year 2021, Payable on 31 May 2022

First quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.09 in 1Q 2021)

Beijing Science Sun Pharmaceutical Co., Ltd. Approves the Profit Distribution of Final Cash Dividend for the Year 2021

Beijing Science Sun Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.84 (vs CN¥0.32 in FY 2020)

Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.32 (vs CN¥0.31 in FY 2019)

New 90-day low: CN¥11.30

Full year 2020 earnings released: EPS CN¥0.31 (vs CN¥0.31 in FY 2019)

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

Beijing Science Sun Pharmaceutical Co., Ltd. Announces Directorate Changes

New 90-day low: CN¥12.45

Investor sentiment deteriorated over the past week

New 90-day low: CN¥13.92

New 90-day low: CN¥16.02

Third quarter earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

New 90-day low - CN¥16.09

First half earnings released

Beijing Science Sun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin